[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-detail-563823-en":53,"doc-seo-563823-105":76},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":5,"data":54},{"doc_id":55,"user_id":56,"nickname":57,"user_avatar":58,"doc_module":9,"category_id":50,"category_name":51,"doc_title":59,"doc_description":60,"doc_content":61,"file_id":62,"file_url":63,"file_type":64,"file_size":65,"view_count":66,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":67,"language":68,"language_code":69,"site_id":70,"html_lang":69,"table_of_contents":71,"faqs":72,"seo_title":73,"seo_description":60,"update_tm":74,"read_time":75},563823,5909892330395,"Fans","https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Antibiotic Guidance for Treatment of Acute Exacerbations of COPD (AECOPD) in Adults - Chronic Obstructive Pulmonary Disease Pathway","Provides clinician guidance for evaluating and managing acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in adults, emphasizing antibiotic stewardship. Antibiotics are not recommended for all patients; bacterial infection is implicated in less than one third of AECOPD. Procalcitonin (PCT) can help decide whether antibiotics and duration are needed, with typical therapy lasting 5 days when used. Antibiotics are guided by exacerbation severity, ventilator support, Pseudomonas risk factors, and beta-lactam allergy, using adapted respiratory status criteria from the 2018 GOLD guidelines.","Antibiotic Guidance for Treatment of Acute Exacerbations of COPD (AECOPD) in Adults  \nAntibiotics are not recommended for all patients with AECOPD as bacterial infection is implicated in less than one-third of AECOPD. Procalcitonin (PCT) may be helpful in determining if antibiotics are necessary or the duration of treatment. All antibiotic dosages listed below are based on normal renal and hepatic function. The typical duration of therapy for AECOPD is 5 days.  \nAntibiotics should only be started or continued in patients with signs and symptoms of a bacterial infection including:  \n1) Increased dyspnea, increased purulence of sputum, and increased volume of sputum OR  \n2) Ventilator support (invasive or non-invasive) for AECOPD  \nPatients with a PCT \u003C0.1 ng/mL are unlikely to benefit from antibiotic administration  \n• Mild exacerbation (no respiratory failure+, FEV1 >50% predicted, \u003C 3 exacerbations/year)  \no 1st line: Doxycycline 100 mg PO BID OR Cefuroxime 500 mg PO BID  \no 2nd line: Azithromycin 500 mg PO daily*  \n• Moderate exacerbation (non-life-threatening respiratory failure+, FEV1 36-50%, ≥ 3 exacerbations/year, ≥65 years of age)  \no 1st line: Amoxicillin-clavulanate 875-125 mg PO BID OR Doxycycline 100 mg PO BID  \no 2nd line: Azithromycin 500 mg PO daily*  \n• Severe exacerbation (life-threatening respiratory failure+, baseline FEV1 ≤35%) OR Requires ventilator support:  \no No risk factors for Pseudomonas aeruginosa:  \n􀂃 Ceftriaxone 1 gram IV every 24 hours (>80 kg: Ceftriaxone 2 grams IV every 24 hours)  \n􀂃 Severe beta-lactam allergy: Levofloxacin 750 mg PO or IV every 24 hours**  \no Risk factors for Pseudomonas aeruginosa (see Table 1):  \n􀂃 1st line: Cefepime 1 gram IV every 6 hours  \n􀂃 2nd line: Piperacillin-tazobactam 4.5 grams IV every 8 hours  \n􀂃 Severe beta-lactam allergy: Aztreonam 2 grams IV every 8 hours + levofloxacin  \n750 mg po or IV every 24 hours**  \n+ Respiratory status adapted from the 2018 GOLD guidelines. See Table 1. For patients with re-admission within 30 days or recurrent AECOPD, consider expert consultation with a pulmonologist.  \n* Consider ECG prior to initiating, especially if other QTc-prolonging medications are present. Alternate therapy may need to be considered in patients at high risk of cardiovascular events.  \n**As of July 2016, the FDA no longer recommends fluoroquinolones for the treatment of acute exacerbations of bronchitis. This therapy should be reserved for severe beta-lactam allergy where no other treatment options are available.  \nChronic Obstructive Pulmonary Disease Pathway  \nPurpose  \nTo provide a framework for the initial evaluation and management of patients admitted with acute exacerbations of chronic obstructive pulmonary disease (COPD) based on recent literature and guidelines. Appropriate management of these exacerbations can have a significant impact on the patient’s morbidity and mortality; therefore, it is important that evidence-based regimens are utilized in these patients. Antibiotics are often used in acute exacerbations of COPD (AECOPD) as bacteria are commonly implicated in these patients; however, exacerbations may be caused by viruses and other environmental factors. This document will provide the clinician with guidance to assist with diagnosis and management of AECOPD. COPD order sets are available within One Chart and contain much of the information below. These order sets should be utilized as they provide a convenient way to provide evidence-based care to patients at Nebraska Medicine.  \nDefinition1  \nChronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disease characterized by inflammation and structural changes leading to decreased airflow. The most common symptoms of COPD include chronic cough, dyspnea, and sputum production. The disease includes emphysema and obstructive bronchiolitis. Chronic bronchitis may be present in patients with COPD, but it is considered tobe a separate disease state. COPD affects millions of patients i","cbCaiaGpEEfXgz9U","https://ap.wps.com/l/cbCaiaGpEEfXgz9U","pdf",434874,4,6,"English","en",105,"# Antibiotic Guidance for Treatment of Acute Exacerbations of COPD (AECOPD) in Adults\n## When to Start or Continue Antibiotics\n## Antibiotic Regimens by Exacerbation Severity\n## Treatment Notes and FDA Guidance\n# Chronic Obstructive Pulmonary Disease Pathway\n## Purpose\n## Definition\n## Diagnosis","[{\"question\":\"When are antibiotics recommended for adults with AECOPD?\",\"answer\":\"Antibiotics should be started or continued only when bacterial infection signs are present, including increased dyspnea with increased sputum purulence/volume, or when ventilator support is required for AECOPD.\"},{\"question\":\"How does procalcitonin (PCT) influence antibiotic decisions and duration?\",\"answer\":\"PCT helps determine whether antibiotics are necessary; patients with PCT \\u003c0.1 ng/mL are unlikely to benefit. When antibiotics are used, the typical duration of therapy for AECOPD is 5 days.\"},{\"question\":\"How are antibiotic choices selected for mild, moderate, and severe exacerbations?\",\"answer\":\"Regimens are selected by severity criteria such as FEV1 and frequency of exacerbations, and whether life-threatening respiratory failure or ventilator support is present. Mild uses options like doxycycline or cefuroxime first line, with azithromycin as second line; moderate includes amoxicillin-clavulanate or doxycycline first line; severe includes ceftriaxone or levofloxacin without Pseudomonas risk factors, and cefepime or piperacillin-tazobactam (plus alternatives for beta-lactam allergy) when Pseudomonas risk factors are present.\"}]","Antibiotic Guidance for Treatment of Acute Exacerbations of COPD (AECOPD) in Adults - Chronic Obstructive Pulmonary Disease Pathway | PDF",1791838755,2,{"code":4,"msg":77,"data":78},"ok",{"site_id":70,"language":69,"slug":79,"title":59,"keywords":80,"description":60,"schema_data":81,"social_meta":135,"head_meta":137,"extra_data":139,"updated_unix":140},"antibiotic-guidance-for-treatment-of-acute-exacerbations-of-copd-aecopd-in-adults-chronic-obstructive-pulmonary-disease-pathway","",{"@graph":82,"@context":134},[83,97,117],{"@type":84,"itemListElement":85},"BreadcrumbList",[86,90,92,95],{"item":87,"name":88,"@type":89,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":91,"name":10,"@type":89,"position":75},"https://docshare.wps.com/template/",{"item":93,"name":51,"@type":89,"position":94},"https://docshare.wps.com/template/general/",3,{"item":96,"name":59,"@type":89,"position":66},"https://docshare.wps.com/template/antibiotic-guidance-for-treatment-of-acute-exacerbations-of-copd-aecopd-in-adults-chronic-obstructive-pulmonary-disease-pathway/563823/",{"url":96,"name":59,"@type":98,"image":99,"author":104,"headline":59,"publisher":106,"fileFormat":109,"inLanguage":69,"description":60,"dateModified":110,"datePublished":111,"encodingFormat":109,"isAccessibleForFree":112,"interactionStatistic":113},"DigitalDocument",{"url":100,"@type":101,"width":102,"height":103},"https://docshare.wps.com/thumbnails/antibiotic-guidance-for-treatment-of-acute-exacerbations-of-copd-aecopd-in-adults-chronic-obstructive-pulmonary-disease-pathway/563823.png","ImageObject",442,249,{"name":57,"@type":105},"Person",{"url":87,"name":107,"@type":108},"DocShare","Organization","application/pdf","2026-10-27","2026-10-12",true,{"@type":114,"interactionType":115,"userInteractionCount":66},"InteractionCounter",{"@type":116},"ViewAction",{"@type":118,"mainEntity":119},"FAQPage",[120,126,130],{"name":121,"@type":122,"acceptedAnswer":123},"When are antibiotics recommended for adults with AECOPD?","Question",{"text":124,"@type":125},"Antibiotics should be started or continued only when bacterial infection signs are present, including increased dyspnea with increased sputum purulence/volume, or when ventilator support is required for AECOPD.","Answer",{"name":127,"@type":122,"acceptedAnswer":128},"How does procalcitonin (PCT) influence antibiotic decisions and duration?",{"text":129,"@type":125},"PCT helps determine whether antibiotics are necessary; patients with PCT \u003C0.1 ng/mL are unlikely to benefit. When antibiotics are used, the typical duration of therapy for AECOPD is 5 days.",{"name":131,"@type":122,"acceptedAnswer":132},"How are antibiotic choices selected for mild, moderate, and severe exacerbations?",{"text":133,"@type":125},"Regimens are selected by severity criteria such as FEV1 and frequency of exacerbations, and whether life-threatening respiratory failure or ventilator support is present. Mild uses options like doxycycline or cefuroxime first line, with azithromycin as second line; moderate includes amoxicillin-clavulanate or doxycycline first line; severe includes ceftriaxone or levofloxacin without Pseudomonas risk factors, and cefepime or piperacillin-tazobactam (plus alternatives for beta-lactam allergy) when Pseudomonas risk factors are present.","https://schema.org",{"og:url":96,"og:type":136,"og:title":59,"og:site_name":107,"og:description":60},"article",{"robots":138,"canonical":96},"index,follow",{"doc_id":55,"site_id":70},1792088754]